Leerink Partnrs Has Pessimistic View of VYGR FY2026 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2026 earnings per share (EPS) estimates for Voyager Therapeutics in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will post earnings per share of ($0.62) for the year, down from their prior estimate of ($0.49). The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics' FY2027 earnings at ($1.36) EPS.

VYGR has been the subject of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an "overweight" rating in a report on Wednesday, March 12th. Wedbush reissued an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group lowered their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Voyager Therapeutics has an average rating of "Buy" and a consensus target price of $13.97.

Voyager Therapeutics Price Performance

Shares of VYGR traded up $0.03 on Friday, hitting $3.16. The company's stock had a trading volume of 338,684 shares, compared to its average volume of 454,689. The company has a market capitalization of $174.45 million, a PE ratio of 4.45 and a beta of 1.02. Voyager Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $9.55. The company has a 50 day moving average price of $3.74 and a 200 day moving average price of $5.30.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.24). The firm had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the firm earned $1.25 earnings per share.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the transaction, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This trade represents a 2.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in VYGR. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics in the fourth quarter valued at about $29,000. Tower Research Capital LLC TRC grew its position in shares of Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after buying an additional 3,077 shares during the period. Picton Mahoney Asset Management increased its stake in shares of Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after acquiring an additional 2,444 shares during the last quarter. Oxford Asset Management LLP acquired a new stake in shares of Voyager Therapeutics in the 4th quarter valued at approximately $60,000. Finally, Tema Etfs LLC bought a new position in Voyager Therapeutics during the 4th quarter worth approximately $85,000. Institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.